{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 69 of 129', 'Hospital Anxiety and Depression Scale (HADS) (Section 10.3.2.10).', '10.3.2.1 Eczema-related Sleep numeric rating scale', 'Subjects will rate how much their eczema interfered with their sleep the last night using an', '11-point NRS (0 indicating that it \\'did not interfere\\' and 10 indicating that it \"completely', \"interfered'). Subjects will complete the Eczema-related Sleep NRS as part of an eDiary each\", 'day in the morning from Week -2 (visit 2) until Week 32. The Eczema-related Sleep NRS is', 'included in the investigator trial file.', '10.3.2.2 Worst Daily Pruritus numeric rating scale', 'Subjects will assess their worst itch severity over the past 24 hours using an 11-point NRS', '(\\'Worst Daily Pruritus NRS\\') with 0 indicating \"no itch\\' and 10 indicating \\'worst itch', \"imaginable'. Subjects will complete the Worst Daily Pruritus NRS as part of an eDiary each\", 'day in the morning from Week -2 (visit 2) until Week 32. The Worst Daily Pruritus NRS is', 'included in the investigator trial file.', '10.3.2.3 Average Daily Pruritus numeric rating scale', 'Subjects will assess their average itch over the past 24 hours using an 11-point NRS', '(\\'Average Daily Pruritus NRS\\') with 0 indicating \"no itch\\' and 10 indicating \"worst itch', \"imaginable' Subjects will complete the Average Daily Pruritus NRS as part of an eDiary each\", 'day in the morning from Week -2 (visit 2) until Week 32. The Average Pruritus NRS is', 'included in the investigator trial file.', '10.3.2.4 Patient Days of Topical Treatment Use', 'Subjects will assess their use of topical AD treatment use over the past 24 hours using a', 'response scale (\\'yes\\', \"no\\'). Subjects will complete the Patient Days of Topical Treatment Use', 'as part of an eDiary each day in the morning from baseline (Week 0 [visit 3]) until Week 32.', 'The Patient Days of Topical Treatment Use is included in the investigator trial file.', '10.3.2.5 Patient Global Impression of Bother', \"The PGI-B is a single item designed to capture the subject's perception of how bothered they\", 'have been by their AD over the past 24 hours at the time of completion. A 5-point categorical', 'response scale will be used (\\'not at all\\', \"slightly\\', \"somewhat\\', \\'a lot\\', \\'very much\\'). Subjects', 'will complete this item as part of the eDiary each day in the morning from Week -2 (visit 2)', 'until Week 32. The PGI-B is included in the investigator trial file.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 70 of 129', '10.3.2.6 Patient Global Impression of Severity', \"The PGI-S is a single item designed to capture the subject's perception of overall eczema\", \"symptom severity over the last 24 hours on a 4-point categorical response scale ('no\", 'symptoms\\' to \"severe\\'). Subjects will complete this item as part of the eDiary each day in the', 'morning from Week -2 (visit 2 2) until Week 32. The PGI-S is included in the investigator trial', 'file.', '10.3.2.7 Patient-Oriented Eczema Measure', 'The POEM is a validated questionnaire used to assess disease symptoms in atopic eczema', 'patients in both clinical practice and clinical trials (30). The tool consists of 7 items each', 'addressing a specific symptom (itching, sleep, bleeding, weeping, cracking, flaking, and', 'dryness). Subject will score how often they have experienced each symptom over the previous', \"week on a 5-point categorical response scale (0 = 'no days'; 1 = '1 to 2 days'; 2 = '3 to\", \"4 days'; 3 = '5 to 6 days'; 4 = 'every day'). The total score is the sum of the 7 items (range:\", '0 to 28) and reflects disease-related morbidity; a high score is indicative of a worse disease', 'severity. The POEM will be completed electronically on the device supplied to the trial site', 'according to the schedule of procedures (Section 4). The POEM is included in the investigator', 'trial file.', '10.3.2.8 Dermatology Life Quality Index', 'The DLQI is a validated questionnaire with content specific to those with dermatology', \"conditions. It consists of 10 items addressing the subject's perception of the impact of their\", 'skin disease on different aspects of their HRQoL over the last week such as dermatology-', 'related symptoms and feelings, daily activities, leisure, work or school, personal relationships,', 'and the treatment (31). Each item is scored on a 4-point Likert scale (0 = \"not at all/not', \"relevant'; 1 = 'a little'; 2 = 'a lot'; 3 = 'very much'). The total score is the sum of the 10 items\", '(0 to 30); a high score is indicative of a poor HRQoL. The DLQI will be completed', 'electronically on the device supplied to the trial site according to the schedule of procedures', '(Section 4). The DLQI is included in the investigator trial file.', '10.3.2.9 EQ-5D-5L', 'The EQ-5D-5L is a standardised measure of health status developed by the EuroQol group to', 'provide a simple, generic measure of health for clinical and economic appraisal (32). The', 'EQ-5D-5L is a self-administered questionnaire used to assess health status \"today\\' and is', 'divided into 2 sections: The first section includes 5 dimensions (mobility, self-care, usual', 'activity, pain/discomfort, and anxiety/depression); each dimension will be assessed by the', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}